MEMORY PROTECT PRO EXPRESS CERTIFICATE - NOVAVAX/BEYOND MEAT/SUNRUN Stock
Certificat
F70085
DE000VK2NJ44
| Market Closed - Borsa Italiana 11:45:00 2026-11-04 EST | ||
| 9.250 EUR | +13.50% |
|
| Current month | +11.45% | ||
| 1 month | -15.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Receive live all our recommendations
on Turbos and Warrants by Email or WhatsApp.
on Turbos and Warrants by Email or WhatsApp.
Chart
NOVAVAX, INC.
Latest news about NOVAVAX, INC.
| Date | Price | Change |
|---|---|---|
| 26-11-04 | €9.250 | +13.50% |
| 26-11-03 | €8.150 | -14.66% |
| 26-11-02 | €9.550 | +15.06% |
| 26-10-30 | €8.300 | -19.42% |
| 26-10-29 | €10.30 | +17.05% |
Static data
| Product type | Certificats Divers |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVAVAX, INC. |
| Issuer |
Vontobel
|
| F70085 | |
| ISIN | DE000VK2NJ44 |
| Date issued | 2025-05-19 |
| Maturity | 2027-11-15 (376 Days) |
| Parity | 1 : 1 |
| Emission price | 100.00 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 111.25 € |
|---|---|
| Lowest since issue | 7.550 € |
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Sector
-
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.65USD
Average target price
14.44USD
Spread / Average Target
+35.63%
- Stock Market
- Certificates
- F70085 Certificat
Select your edition
All financial news and data tailored to specific country editions
Vontobel
















